Document is current
Any future updates will be listed below
-
Authors
Czeisler, Mark É. https://orcid.org/0000-0003-3100-7347
Howard, Mark E. https://orcid.org/0000-0001-7772-1496
Robbins, Rebecca https://orcid.org/0000-0003-0288-2505
Barger, Laura K. https://orcid.org/0000-0001-8547-7331
Facer-Childs, Elise R. https://orcid.org/0000-0003-4549-9266
Rajaratnam, Shantha M. W. https://orcid.org/0000-0001-7527-8558
Czeisler, Charles A. https://orcid.org/0000-0002-7408-1849
-
Funding
Funding for this research was provided by:
National Institute for Occupational Safety and Health (R01-OH-010300, R01-OH-010300)
Institute for Breahting and Sleep at Austin Health
Turner Institute for Brain and Mental Health
Philips
Australian-American Fulbright Commission
Commonwealth Scientific and Industrial Research Organisation
- License Information
-
More Information
Article History
Received: 6 May 2020
Accepted: 8 February 2021
First Online: 15 March 2021
Ethics approval and consent to participate
: The study protocol was approved by the Monash University Human Research Ethics Committee (#24036) and conducted in accordance with ethical guidelines. This activity was also reviewed by the United States Centers for Disease Control and Prevention (CDC), which affirmed that the activity was conducted consistent with applicable federal law and CDC policies for the protection of human participants from research risks: 45 Code of Federal Regulations (CFR) part 46, 21 CFR part 56; 42 United States Code (USC) Section 241(d); 5 USC Section 552a; 44 USC Section 3501 et seq. Respondents were informed of the study purposes and provided informed consent electronically prior to commencement. Investigators received anonymised responses.
: Not applicable.
: CAC reports grants from Cephalon Inc., Jazz Pharmaceuticals Plc., Inc., Philips Respironics, Inc., Regeneron Pharmaceuticals, and Sanofi S.A.; and personal fees from Institute of Digital Media and Child Development, Klarman Family Foundation, Teva Pharma Australia, and Vanda Pharmaceuticals. In addition, CAC holds an equity interest in Vanda Pharmaceuticals, Inc. CAC receives royalties from Philips Respironics, Inc. for the Actiwatch-2 and Actiwatch-Spectrum devices. Interests for CAC were reviewed and managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict of interest policies. MÉC, MEH, RR, LKB, ERF-C, and SMWR declare no potential conflicts of interest.
